ERYTHROPOIETIN IMPROVES THE POSTRESUSCITATION MYOCARDIAL DYSFUNCTION AND SURVIVAL IN THE ASPHYXIA-INDUCED CARDIAC ARREST MODEL

Shock ◽  
2007 ◽  
Vol 28 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Chien-Hua Huang ◽  
Chiung-Yuan Hsu ◽  
Huei-Wen Chen ◽  
Min-Shan Tsai ◽  
Hsiao-Ju Cheng ◽  
...  
Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Chien-Hua Huang ◽  
Chiung-Yuan Hsu ◽  
Huei-Wen Chen ◽  
Wei-Tien Chang ◽  
Wen-Jone Chen

Introduction: The myocardial dysfunction carries high mortality rate in the postresuscitation period. Interventions for improving myocardial dysfunction may improve the outcomes of resuscitated victims. The erythropoietin (EPO) provides protective effects for the myocardium with ischemia-reperfusion injuries. However, its effects on the treatment of cardiopulmonary arrest and post-resuscitation myocardial dysfunction remain unknown. Hypothesis: EPO can improve the postresuscitation myocardial dysfunction in an appropriate therapeutic time window. Methods: Asphyxia-induced cardiac arrest was performed in male adult Wistar rats. Cardiopulmonary resuscitation including chest compressions, mechanical ventilation and epinephrine (0.01 mg/kg) was begun after 6.5 or 9.5 minutes of asphyxia. Animals were randomized to undergo treatment with intravenous EPO (5000 U/kg) or equivalent volume of 0.9% saline placebo. These agents were administrated 3 minutes after the return of spontaneous circulation. Results: The better left ventricular dP/dt 40 (2958±827 vs. 1321±1200 mmHg/s, P<0.05) and maximal -dP/dt (2562±546 vs. 745±877 mmHg/s, P<0.05) at 120 minutes after cardiac arrest, and better left ventricular fraction shortening (32.0 ± 2.0 vs. 24 ± 6.7 %, P<0.05) by echocardiography at 90 minutes after cardiac arrest were noted in the EPO-treated group compared to the control group in the condition of 6.5 minutes of asphyxia. The EPO treated group had better neurological recovery at 24 hours after resuscitation. Survival rate at 72 hours after 6.5 minutes of asphyxia was better in the EPO-treated group (50% vs. 20 %, P=0.02). No animal survived 72 hours after 9.5 minutes of asphyxia either in EPO-treated or control group. More activation of cardiac Akt and ERK 42/44 signaling pathways were noted in the EPO-treated group than the control group. Conclusions: EPO has the potential to improve postresuscitation myocardial dysfunction and short term survival in rats after asphyxia-induced cardiac arrest in an appropriate therapeutic time window.


1955 ◽  
Vol 30 (5) ◽  
pp. 620-625 ◽  
Author(s):  
Conrad R. Lam ◽  
Thomas Geoghegan ◽  
Alfredo Lepore

2006 ◽  
Vol 96 (3) ◽  
pp. 310-316 ◽  
Author(s):  
K Plaschke ◽  
D Boeckler ◽  
H Schumacher ◽  
E Martin ◽  
H.J. Bardenheuer

Circulation ◽  
2021 ◽  
Vol 144 (Suppl_2) ◽  
Author(s):  
Abhishek Bhardwaj ◽  
Mahmoud Alwakeel ◽  
Siddharth Dugar ◽  
sudhir krishnan ◽  
Xiaofeng Wang ◽  
...  

Introduction: Post resuscitation myocardial dysfunction (PRMD) is common after out-of-hospital cardiac arrest. While PRMD is a known cause of post-resuscitation circulatory failure, few studies have reported associations between PRMD and neurologic outcome or survival. Further, little is known about PRMD after in-hospital cardiac arrest (IHCA) nor on the incidence and prognosis of PRMD in COVID-19 IHCA. We sought to evaluate the incidence of PRMD in a multicenter cohort of resuscitated COVID-19 IHCA patients. Study Population and Methods: We included adult patients (≥18 y) admitted to multiple hospitals of Cleveland Clinic Health System. Patients who attained ROSC with an initial echocardiogram (EC) in the 72 hours post-arrest were included. Data were extracted from a data registry and electronic medical records. Results: From 03/2020-10/2020, 58 patients with COVID-19 had IHCA. ROSC was noted in 35 patients (60.3%), 27 (46.6%) were alive at 24 h and 13 patients (22.4%) survived to hospital discharge. Of the 35 patients who had ROSC, 14 patients (40%) had an EC within 72 h. The median age of this cohort was 67 y (IQR 47 - 73); 71% were male, and median BMI of 28 (IQR 27 - 34), and admission APACHE II score was 13 (IQR 11 - 19). One third of the patients (36%) were mechanically ventilated before arrest and 43% were on vasopressors. Initial arrest rhythms were: PEA/Asystole, 79%; and VF/VT, 21%. Most patients (93%) received manual chest compression with median CPR duration of 5 min (IQR 2 - 10). The median time of obtaining first EC post-ROSC in these 14 patients was 22 hours (IQR 6 - 62). 7/14 (50%) of the patient had systolic dysfunction on initial EC (6 had global dysfunction, 1 with regional wall motion abnormality, and 4/7 had combined LV and RV systolic dysfunction). 5/14 patients had a follow up EC with a median time of 43 days. 2/5 had normal initial EC and 3 out of these 5 patients who initially had PMRD showed complete recovery in their LV and RV systolic function. Conclusion: We report a case series of PRMD in COVID-19 patients who experienced IHCA. We found that PMRD is seen in half of the patients. Most patients with PMRD recovered to normal RV and LV function, consistent with prior studies of non-COVID-19 arrest EC.


2017 ◽  
Vol 1674 ◽  
pp. 42-54 ◽  
Author(s):  
Gerburg Keilhoff ◽  
Torben Esser ◽  
Maximilian Titze ◽  
Uwe Ebmeyer ◽  
Lorenz Schild

Sign in / Sign up

Export Citation Format

Share Document